AbbVie (ABBV) Net Income - Minority (2020 - 2021)
AbbVie (ABBV) reported Net Income - Minority of -$25.0 million for Q2 2021, down 4.17% year-over-year from -$26.1 million in Q2 2020, and down 8.7% quarter-over-quarter from -$23.0 million in Q1 2021.
AbbVie (ABBV) Net Income - Minority (2020 - 2021) Analysis & Trends
AbbVie (ABBV) has 2 years of Net Income - Minority data on file, last reported at -$25.0 million in Q2 2021.
- Net Income - Minority for Q2 2021 came in at -$25.0 million, down 4.17% year-over-year; the trailing twelve-month figure through Jun 2021 was -$25.0 million (down 4.17% YoY), and the FY2020 annual result was -$21.0 million, changed N/A from the prior year.
- Net Income - Minority slipped to -$25.0 million in Q2 2021 per ABBV's latest filing, from -$23.0 million in the prior quarter.
- Over five years, Net Income - Minority peaked at -$19.0 million in Q3 2020 and troughed at -$25.0 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income - Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | - |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -25.00 Mn |
| Mar 31, 2021 | -23.00 Mn |
| Dec 31, 2020 | -21.00 Mn |
| Sep 30, 2020 | -19.00 Mn |
| Jun 30, 2020 | -24.00 Mn |